Clinical Trial

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Study acronym: MERCURY
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a window-of-opportunity study for patients with resectable Merkel Cell Carcinoma. The aim of this study is to test the activity of a course of chemo-immunotherapy followed by surgery in patients with operable Merkel cell carcinoma. Participants will receive one cycle of retifanlimab plus platinum-etoposide chemotherapy prior to their scheduled surgery.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-21; most recent amendment 2026-01-13.
Status change: Recruiting → Active, Not Recruiting 2026-01-13
Status change: Not Yet Recruiting → Recruiting 2023-01-04
Trial Details
NCT Number NCT05594290
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Conditions Merkel Cell Carcinoma
Enrollment 36 participants
Start Date 2022-12-07
Primary Completion 2025-11-15 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-14